ME02395B - Kombinovana terapija sa antitumorskim alkaloidima - Google Patents
Kombinovana terapija sa antitumorskim alkaloidimaInfo
- Publication number
- ME02395B ME02395B MEP-2016-54A MEP5416A ME02395B ME 02395 B ME02395 B ME 02395B ME P5416 A MEP5416 A ME P5416A ME 02395 B ME02395 B ME 02395B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- antimetabolite
- use according
- Prior art date
Links
- 229930013930 alkaloid Natural products 0.000 title 1
- 150000003797 alkaloid derivatives Chemical class 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 15
- 230000000340 anti-metabolite Effects 0.000 claims 12
- 229940100197 antimetabolite Drugs 0.000 claims 12
- 239000002256 antimetabolite Substances 0.000 claims 12
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229960002949 fluorouracil Drugs 0.000 claims 5
- 229960005277 gemcitabine Drugs 0.000 claims 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960000485 methotrexate Drugs 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 229960000684 cytarabine Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000011885 synergistic combination Substances 0.000 claims 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 2
- 229960003896 aminopterin Drugs 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 229960003603 decitabine Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960000961 floxuridine Drugs 0.000 claims 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960004432 raltitrexed Drugs 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- -1 cytarin Chemical compound 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
1. РМ01183, ili njegova farmaceutski prihvatljiva so, za primjenu u liječenju kancera, koja sadrži administraciju terapeutski efektivne količine РМ01183, ili njegove farmaceutski prihvatljive soli, u sinergističkičkoj kombinaciji sa terapeutski efektivnom količinom antimetabolita, pri čemu је antimetabolit izabran između 5-fluorouracila, gemcitabina, citaraЬina, kcapecitabina, decitabina, floksuridina, aminopterina, metotreksata, pemetrekseda i raltitrekseda.
2. РМ01183, ili njegova farmaceutski prihvatljiva so, za primjenu u povećanju terapeutske efikasnosti antimetabolita u liječenju kancera, koja sadrži administraciju pacijentu kome је to potrebno terapeutski efektivne količine РМ01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj komЬinaciji sa pomenutim antimetabolitom, pri čemu је antimetabolit izabran izmedu 5-fluorouracila, gemcitabina, citaraЬina, kapecitabina, decitabina, floksuridina, aminopterina, metotreksata, pemetrekseda i raltitrekseda.
3. РМ01183, ili njegova farmaceutski prihvatljiva so, za primjenu prema zahtjevu 1 ili 2, pri čemu РМ01183, ili njegova farmaceutski prihvatljiva so, i antimetabolit formiraju deo istog medikamenta.
4. РМ01183, ili njegova farmaceutski prihvatljiva so, za primjenu prema zahtjevu 1 ili 2, pri cemu su РМ01183, ili njegova farmaceutski prihvatljiva so, i antimetabolit pripremljeni kao posebni medikamenti za administraciju u istom vremenskom trenutku ili u različitim vremenskim trenucima.
5. РМ01183, ili njegova farmaceutski prihvatljiva so, za primjenu prema zahtjevu 4, pri cemu su РМ01183, ili njegova farmaceutski prihvatljiva so, i antimetabolit pripremljeni kao posebni medikamenti za administraciju u različitim vremenskim trenucima.
6. РМО1183, ili njegova farmaceutski prihvatljiva so, za primjenu prema bilo kom od prethodnih zahtjeva, pri čemu је antimetabolit izabran između 5-fluorouracila, kapecitabina, gemcitabina, citarabina i metotreksata.
7. РМО1183, ili njegova farmaceutski prihvatljiva so, za primjenu prema zahtjevu 6, pri cemu је antimetabolit izabran između 5-fluorouracila, gemcitabina, citarabina i metotreksata.
8. РМО1183, ili njegova farmaceutski prihvatljiva so, za primjenu prema Ьilo kom od prethodnih zahtjeva, pri čemu је kancer koji treba da se liječi izabran između kancera pluća, sarkoma, malignog melanoma, karcinoma mokraćne bešike, kancera prostate, karcinoma pankreasa, kancera štitne žlijezde, karcinoma želuca, kancera jajnika, hepatoma, kancera dojke, kolorektalnog kancera, kancera bubrega, kancera jednjaka, neuroЫastoma, kancera mozga, kancera grlića materice, analnog kancera, kancera testisa, leukemije, multiplog mijeloma i limfoma.
9. РМ01183, ili njegova farmaceutski prihvatljiva so, za primjenu prema zahtjevu 8 pri čemu је kancer koji treba da se lijeći izabran između kancera pluća, sarkoma, malignog melanoma, kancera prostate, karcinoma pankreasa, karcinoma želuca, kancera jajnika, hepatoma, kancera dojke, kolorektalnog kancera, kancera bubrega, kancera mozga, leukemije i limfoma.
10. Kit za prijmenu u lijčenju kancera koji sadrži dozirani oblik РМ01183, ili njegove farmaceutski prihvatljive soli; i dozirani oblik antimetabolita, pri čemu је antimetabolit izabran između 5-fluorouracila, gemcitabina, citarabina, kapecitabina, decitabina, floksuridina, aminopterina, metotreksata, pemetrekseda i raltitrekseda; i uputstvo za upotrebu obа lijeka u sinergističkoj kombinaciji koja је opisana u bilo kom od prethodnih zahtjeva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382300 | 2010-11-12 | ||
| PCT/EP2011/069976 WO2012062920A1 (en) | 2010-11-12 | 2011-11-11 | Combination therapy with an antitumor alkaloid |
| EP11781807.0A EP2637663B1 (en) | 2010-11-12 | 2011-11-11 | Combination therapy with an antitumor alkaloid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02395B true ME02395B (me) | 2016-09-20 |
Family
ID=44936282
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-77A ME03501B (me) | 2010-11-12 | 2011-11-11 | Kombinovana terapija sa antitumorskim antibiotikom |
| MEP-2019-91A ME03408B (me) | 2010-11-12 | 2011-11-11 | KOMBINOVANA TERAPIJA SA INHIBITOROM MItOZE |
| MEP-2016-54A ME02395B (me) | 2010-11-12 | 2011-11-11 | Kombinovana terapija sa antitumorskim alkaloidima |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-77A ME03501B (me) | 2010-11-12 | 2011-11-11 | Kombinovana terapija sa antitumorskim antibiotikom |
| MEP-2019-91A ME03408B (me) | 2010-11-12 | 2011-11-11 | KOMBINOVANA TERAPIJA SA INHIBITOROM MItOZE |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US20130266666A1 (me) |
| EP (6) | EP2786754B1 (me) |
| JP (4) | JP6382516B2 (me) |
| KR (9) | KR20170096065A (me) |
| CN (3) | CN105664165A (me) |
| AU (4) | AU2011328004C1 (me) |
| BR (4) | BR122017028570B1 (me) |
| CA (4) | CA2995033C (me) |
| CY (4) | CY1117466T1 (me) |
| DK (4) | DK2637663T3 (me) |
| ES (4) | ES2790414T3 (me) |
| HK (1) | HK1202422A1 (me) |
| HR (4) | HRP20160361T1 (me) |
| HU (4) | HUE042802T2 (me) |
| LT (3) | LT2786753T (me) |
| ME (3) | ME03501B (me) |
| PL (4) | PL2637663T3 (me) |
| PT (3) | PT2786753T (me) |
| RS (4) | RS58609B1 (me) |
| RU (4) | RU2605335C2 (me) |
| SI (4) | SI2786753T1 (me) |
| SM (4) | SMT201900190T1 (me) |
| TR (2) | TR201904459T4 (me) |
| WO (1) | WO2012062920A1 (me) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| CA2995033C (en) * | 2010-11-12 | 2020-04-28 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| KR101588949B1 (ko) * | 2014-03-13 | 2016-01-29 | 아주대학교산학협력단 | 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제 |
| US11326210B2 (en) * | 2015-01-30 | 2022-05-10 | Glax Llc | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer |
| EP3402529A1 (en) * | 2016-01-11 | 2018-11-21 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| TWI807411B (zh) | 2017-04-27 | 2023-07-01 | 西班牙商瑪製藥股份有限公司 | 抗腫瘤化合物 |
| CA3117666A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| AU2020342483A1 (en) * | 2019-09-03 | 2022-04-14 | Pharma Mar, S.A. | Lurbinectedin in the treatment of malignant mesothelioma |
| KR20210049403A (ko) * | 2019-10-25 | 2021-05-06 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 조성물 |
| EP4061372A1 (en) * | 2019-11-21 | 2022-09-28 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
| WO2021228414A1 (en) * | 2020-05-14 | 2021-11-18 | Pharma Mar, S.A. | Methods of treating small cell lung cancer with lurbinectedin formulations |
| MA56827B2 (fr) * | 2019-11-21 | 2023-09-27 | Pharma Mar Sa | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine |
| CN111298122B (zh) * | 2019-12-04 | 2021-12-21 | 哈尔滨商业大学 | 用于治疗小细胞肺癌的药物组合物及其应用 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN113491771A (zh) * | 2020-03-18 | 2021-10-12 | 苏州大学 | 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用 |
| EP4141110A4 (en) | 2020-04-24 | 2025-04-09 | Sf Biotech Laboratuvar Danismanlik Anonim Sirketi | Method for producing particles of bacteriophages of the genus levivirus |
| KR102637904B1 (ko) * | 2020-07-01 | 2024-02-19 | 주식회사 뉴캔서큐어바이오 | 3-케토아실 CoA 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| CN118576599A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途 |
| CN112870194B (zh) * | 2021-01-06 | 2022-06-21 | 广州医科大学附属肿瘤医院 | 治疗肝癌的组合物及其应用 |
| CN115957188A (zh) * | 2021-06-17 | 2023-04-14 | 中国医学科学院医药生物技术研究所 | 米铂脂质体在抗耐药性肿瘤的应用 |
| CN115246846B (zh) * | 2021-11-19 | 2024-10-01 | 江苏慧聚药业股份有限公司 | 卢比替定新晶型及其制备 |
| WO2023165603A1 (en) * | 2022-03-03 | 2023-09-07 | Zai Lab (Shanghai) Co., Ltd. | Dna-pk inhibitor and combination use thereof |
| WO2024188978A1 (en) * | 2023-03-10 | 2024-09-19 | Pharma Mar, S.A. | Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer |
| EP4563149A1 (en) * | 2023-11-30 | 2025-06-04 | Pharma Mar, S.A. | Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers |
| WO2025228596A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer |
| TW202547488A (zh) | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合 |
| CN120501841A (zh) * | 2025-05-21 | 2025-08-19 | 广州爱索达生物医药技术有限公司 | 一种降低化疗治疗副作用的外泌体组合物及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
| JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| WO1987007610A2 (en) | 1986-06-09 | 1987-12-17 | University Of Illinois | Ecteinascidins 729, 743, 745, 759a, 759b and 770 |
| US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| SK285669B6 (sk) | 1998-04-06 | 2007-06-07 | The Board Of Trustees Of The University Of Illinois | Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie |
| US6316214B1 (en) | 1998-05-11 | 2001-11-13 | The Board Of Trustees Of The University Of Illinois | ETM-775 metabolite of ecteinascidin 743 |
| US6124292A (en) | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| JP2003520801A (ja) | 2000-01-19 | 2003-07-08 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成 |
| ATE299146T1 (de) | 2000-04-12 | 2005-07-15 | Pharma Mar Sa | Ecteinaschidin derivate mit antikrebs wirkung |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| JP4391083B2 (ja) * | 2000-11-06 | 2009-12-24 | ファルマ・マール・ソシエダード・アノニマ | 効果的な抗腫瘍治療 |
| SE0102232L (sv) * | 2001-06-25 | 2003-02-06 | Anoto Ab | Förfarande och anordning i ett digitalt kommunikationssystem |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| CN1681495B (zh) * | 2002-08-19 | 2010-05-12 | 辉瑞产品公司 | 用于治疗过度增生性疾病的组合物 |
| MXPA05004133A (es) | 2002-10-18 | 2005-10-05 | Pharma Mar Sau | Nuevos compuestos antitumorales. |
| FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| US7393277B2 (en) * | 2003-08-25 | 2008-07-01 | Igt | Horseshoe payline system and games using that system |
| CA2544320A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Method of treating cancer using a combination comprising et-743 and 5-fluorouracil |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| EP1691809A1 (en) * | 2003-11-14 | 2006-08-23 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| MXPA06013902A (es) * | 2004-05-28 | 2007-01-26 | Pfizer Prod Inc | Procedimiento para tratar el crecimiento de celulas anormal. |
| KR101188691B1 (ko) | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| JP5345323B2 (ja) | 2004-12-15 | 2013-11-20 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 癌を処置するための治療剤の組合せ |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| MX2008010999A (es) * | 2006-02-28 | 2008-09-08 | Pharma Mar Sa | Tratamientos anti-tumor mejorados. |
| EP2307003A2 (en) * | 2008-05-16 | 2011-04-13 | Pharma Mar S.A. | Combination therapy with pm00104 and another antitumor agent |
| CA2995033C (en) * | 2010-11-12 | 2020-04-28 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
-
2011
- 2011-11-11 CA CA2995033A patent/CA2995033C/en active Active
- 2011-11-11 PL PL11781807T patent/PL2637663T3/pl unknown
- 2011-11-11 EP EP14175268.3A patent/EP2786754B1/en active Active
- 2011-11-11 HU HUE14175259A patent/HUE042802T2/hu unknown
- 2011-11-11 EP EP20155618.0A patent/EP3666275A3/en not_active Withdrawn
- 2011-11-11 ME MEP-2019-77A patent/ME03501B/me unknown
- 2011-11-11 ME MEP-2019-91A patent/ME03408B/me unknown
- 2011-11-11 ME MEP-2016-54A patent/ME02395B/me unknown
- 2011-11-11 ES ES14175282T patent/ES2790414T3/es active Active
- 2011-11-11 EP EP14175282.4A patent/EP2786756B1/en active Active
- 2011-11-11 KR KR1020177022535A patent/KR20170096065A/ko not_active Ceased
- 2011-11-11 LT LTEP14175259.2T patent/LT2786753T/lt unknown
- 2011-11-11 PL PL14175268T patent/PL2786754T3/pl unknown
- 2011-11-11 BR BR122017028570-0A patent/BR122017028570B1/pt active IP Right Grant
- 2011-11-11 RS RS20190397A patent/RS58609B1/sr unknown
- 2011-11-11 CN CN201610032547.9A patent/CN105664165A/zh active Pending
- 2011-11-11 RS RS20190380A patent/RS58608B1/sr unknown
- 2011-11-11 WO PCT/EP2011/069976 patent/WO2012062920A1/en not_active Ceased
- 2011-11-11 CA CA2995025A patent/CA2995025C/en active Active
- 2011-11-11 SI SI201131699T patent/SI2786753T1/sl unknown
- 2011-11-11 PT PT14175259T patent/PT2786753T/pt unknown
- 2011-11-11 KR KR1020177013350A patent/KR20170058454A/ko not_active Withdrawn
- 2011-11-11 PL PL14175259T patent/PL2786753T3/pl unknown
- 2011-11-11 SM SM20190190T patent/SMT201900190T1/it unknown
- 2011-11-11 EP EP11781807.0A patent/EP2637663B1/en active Active
- 2011-11-11 RU RU2013126630/15A patent/RU2605335C2/ru active
- 2011-11-11 PT PT141752824T patent/PT2786756T/pt unknown
- 2011-11-11 RU RU2016144668A patent/RU2743643C2/ru active
- 2011-11-11 PL PL14175282T patent/PL2786756T3/pl unknown
- 2011-11-11 ES ES11781807.0T patent/ES2569180T3/es active Active
- 2011-11-11 KR KR1020137015020A patent/KR101716804B1/ko active Active
- 2011-11-11 HR HRP20160361TT patent/HRP20160361T1/hr unknown
- 2011-11-11 ES ES14175259T patent/ES2719052T3/es active Active
- 2011-11-11 KR KR1020167019709A patent/KR20160088956A/ko not_active Ceased
- 2011-11-11 HU HUE14175282A patent/HUE049389T2/hu unknown
- 2011-11-11 TR TR2019/04459T patent/TR201904459T4/tr unknown
- 2011-11-11 DK DK11781807.0T patent/DK2637663T3/en active
- 2011-11-11 KR KR1020217011747A patent/KR102452022B1/ko active Active
- 2011-11-11 AU AU2011328004A patent/AU2011328004C1/en active Active
- 2011-11-11 KR KR1020177013349A patent/KR20170057472A/ko not_active Withdrawn
- 2011-11-11 KR KR1020197033700A patent/KR102301175B1/ko active Active
- 2011-11-11 DK DK14175282.4T patent/DK2786756T3/da active
- 2011-11-11 RS RS20160181A patent/RS54648B1/sr unknown
- 2011-11-11 CA CA2995018A patent/CA2995018C/en active Active
- 2011-11-11 SI SI201131880T patent/SI2786756T1/sl unknown
- 2011-11-11 JP JP2013538215A patent/JP6382516B2/ja active Active
- 2011-11-11 BR BR112013011480-0A patent/BR112013011480B1/pt active IP Right Grant
- 2011-11-11 KR KR1020177031575A patent/KR102247982B1/ko active Active
- 2011-11-11 BR BR122017028566-1A patent/BR122017028566B1/pt active IP Right Grant
- 2011-11-11 ES ES14175268T patent/ES2719091T3/es active Active
- 2011-11-11 HU HUE14175268A patent/HUE042801T2/hu unknown
- 2011-11-11 SM SM20200211T patent/SMT202000211T1/it unknown
- 2011-11-11 LT LTEP14175268.3T patent/LT2786754T/lt unknown
- 2011-11-11 KR KR1020177022534A patent/KR20170096224A/ko not_active Ceased
- 2011-11-11 CA CA2817420A patent/CA2817420C/en active Active
- 2011-11-11 US US13/884,874 patent/US20130266666A1/en not_active Abandoned
- 2011-11-11 SI SI201131698T patent/SI2786754T1/sl unknown
- 2011-11-11 CN CN201710123189.7A patent/CN106860870B/zh active Active
- 2011-11-11 LT LTEP14175282.4T patent/LT2786756T/lt unknown
- 2011-11-11 SM SM20190186T patent/SMT201900186T1/it unknown
- 2011-11-11 CN CN201180063925.5A patent/CN103282037B/zh active Active
- 2011-11-11 SI SI201130769A patent/SI2637663T1/sl unknown
- 2011-11-11 TR TR2019/03859T patent/TR201903859T4/tr unknown
- 2011-11-11 BR BR122017028568-8A patent/BR122017028568B1/pt active IP Right Grant
- 2011-11-11 EP EP14175275.8A patent/EP2786755A3/en not_active Withdrawn
- 2011-11-11 RS RS20200506A patent/RS60236B1/sr unknown
- 2011-11-11 PT PT14175268T patent/PT2786754T/pt unknown
- 2011-11-11 HU HUE11781807A patent/HUE027516T2/en unknown
- 2011-11-11 DK DK14175259.2T patent/DK2786753T3/en active
- 2011-11-11 DK DK14175268.3T patent/DK2786754T3/en active
- 2011-11-11 EP EP14175259.2A patent/EP2786753B1/en active Active
-
2014
- 2014-02-24 HK HK15102911.5A patent/HK1202422A1/en unknown
-
2016
- 2016-01-13 AU AU2016200191A patent/AU2016200191B2/en active Active
- 2016-04-19 SM SM201600112T patent/SMT201600112B/it unknown
- 2016-04-22 CY CY20161100333T patent/CY1117466T1/el unknown
- 2016-05-02 JP JP2016092369A patent/JP6723815B2/ja active Active
-
2017
- 2017-09-21 US US15/711,478 patent/US20180008602A1/en not_active Abandoned
- 2017-11-28 US US15/824,506 patent/US20180078550A1/en not_active Abandoned
- 2017-11-28 US US15/824,551 patent/US11590129B2/en active Active
- 2017-12-11 AU AU2017276155A patent/AU2017276155B2/en active Active
- 2017-12-11 AU AU2017276157A patent/AU2017276157B2/en active Active
-
2018
- 2018-01-19 RU RU2018102078A patent/RU2757373C2/ru active
- 2018-01-19 RU RU2018102080A patent/RU2767664C2/ru active
- 2018-03-27 JP JP2018059776A patent/JP6724055B2/ja active Active
- 2018-03-27 JP JP2018059777A patent/JP6724056B2/ja active Active
-
2019
- 2019-03-21 HR HRP20190554TT patent/HRP20190554T1/hr unknown
- 2019-03-22 HR HRP20190565TT patent/HRP20190565T1/hr unknown
- 2019-03-29 CY CY20191100362T patent/CY1121501T1/el unknown
- 2019-03-29 CY CY20191100361T patent/CY1121504T1/el unknown
-
2020
- 2020-04-30 HR HRP20200696TT patent/HRP20200696T1/hr unknown
- 2020-05-08 CY CY20201100423T patent/CY1122904T1/el unknown
-
2023
- 2023-01-11 US US18/095,877 patent/US20230404999A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02395B (me) | Kombinovana terapija sa antitumorskim alkaloidima | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| JP2006504723A5 (me) | ||
| JP2012082215A5 (me) | ||
| JP2014524469A5 (me) | ||
| RU2008138560A (ru) | Улучшенные способы лечения опухолей | |
| RU2010140890A (ru) | Улучшенные способы противоопухолевого лечения | |
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| HRP20201819T1 (hr) | Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol | |
| JP5113038B2 (ja) | 癌治療用キットおよび癌治療用医薬組成物 | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| JP2015507020A5 (me) | ||
| RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
| Mornex et al. | Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art | |
| JP2017516827A5 (me) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| KR101226631B1 (ko) | 항암 치료 방법 | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| JP2011500650A5 (me) | ||
| RU2015145948A (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| CN104146999B (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
| Kano et al. | Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines | |
| WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer |